COMMUNIQUÉS West-GlobeNewswire

Deep integration of proven AI tools into Philips cardiovascular ultrasound systems to better diagnose more cardiac disease patients
04/06/2024
June 4, 2024 New FDA-cleared AI-enabled applications include the industry’s first automated tool for segmental wall motion scoring of the heart to quickly and objectively identify disorders including coronary artery [...]
Aviv Clinics Announces Case Study Showing Benefits of Hyperbaric Oxygen Therapy for Military Post-Traumatic Stress Disorder in Elderly Veterans
04/06/2024
Findings underscore the potential of HBOT as a novel therapeutic approach for elderly individuals with persistent PTSD, even decades after the traumatic event ORLANDO, Fla., June 04, 2024 (GLOBE NEWSWIRE) -- Aviv [...]
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
04/06/2024
--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p< 0.001)-- --Stabilization in Left Ventricular Ejection Fraction (LVEF [...]
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
04/06/2024
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference
04/06/2024
MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX) , a clinical stage company focused on stem cell-based therapies, today announced that [...]
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
04/06/2024
Predictive Oncology’s organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture market is projected to grow by more than 14% annually, from $1.4 [...]
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
04/06/2024
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1 Anticipate potential proof-of-concept data available in the first half of 2025 SOUTH SAN FRANSCISO, Calif., June 04, [...]
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
04/06/2024
ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy SOLANA BEACH, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical [...]
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
04/06/2024
HOUSTON, TX, June 04, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) ( Nasdaq: NXL; NXLIW ) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that [...]
XORTX to Present at BIO International Convention 2024
04/06/2024
CALGARY, June 04, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative [...]
Inspire Medical Systems, Inc. to Present at the Truist Securities Medtech Conference
04/06/2024
MINNEAPOLIS, June 04, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
04/06/2024
NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, [...]
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
04/06/2024
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and [...]
Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary
04/06/2024
PALO ALTO, Calif. and NEEDHAM, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Bitterroot Bio, a pioneering biotechnology company focused on developing innovative medicines in the field of cardio-immunology, today announced [...]
American Oncology Network Announces the Research Studies Presented at the ASCO 2024 Annual Meeting
04/06/2024
AON physicians and leaders present their latest cancer findings with fellow thought leaders at the annual conference. FORT MYERS, Fla., June 04, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), [...]
STRATA Skin Sciences to Participate in June Dermatology Conferences
04/06/2024
HORSHAM, Penn., June 04, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
04/06/2024
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, [...]
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
04/06/2024
HOUSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology [...]
Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
04/06/2024
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+ head and neck squamous cell carcinoma (HNSCC) treated with CUE-101 and KEYTRUDA ® ( [...]

Pages